FreeOx Biotech

About:

FreeOx Biotech develops medicines to reduce the effects of oxidative stress in the organism.

Top Investors: Montserrat Esteve, Javier Alsina

Description:

Based on the knowledge of oxidative stress and uric acid, Freeox Biotech is developing neuroprotective therapies to reduce the damage resulting from ischemia and in this way improve the recovery of the patients. Ox-01 is Uric Acid used as a medicinal product. Ox-01 has a proven effect in preventing the damage caused by reperfusion after stroke. Ox-02 Uricoline is a molecule resulting from the association of Ox-01 and Citicoline. Citicoline is an intermediate in the generation of phosphatidylcholine from choline.

Total Funding Amount:

2.2M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Barcelona, Catalonia, Spain

Founded Date:

2017-03-01

Contact Email:

info(AT)freeoxbiotech.com

Founders:

Carlos Lurigados, Joan Bigorra, Tudor Jovin, Ángel Chamorro, Ángel Honrado

Number of Employees:

1-10

Last Funding Date:

2023-12-05

IPO Status:

Private

Industries: